Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lichtlen

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2004
Loss of metal transcription factor-1 suppresses tumor growth through enhanced matrix depositionZishan A Haroon, Khalid Amin, Peter Lichtlen, et al.
Advances in Therapy|April 9, 2021
Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional ConstipationAtoya Adams, Charles Barish, Angel Chen, et al.
Ophthalmology|March 16, 2013
Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eyeMichael A Thiel, Andreas Wild, Martin K Schmid, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 1, 2004
Metal-responsive transcription factor-1 (MTF-1) is essential for embryonic liver development and heavy metal detoxification in the adult liverYing Wang, Ursula Wimmer, Peter Lichtlen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2021
Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term ExtensionMarc A Benninga, Sunny Z Hussain, Manu R Sood, et al.
Oncoimmunology|July 17, 2023
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelinDaniel Snell, Tea Gunde, Stefan Warmuth, et al.
JID Innovations : Skin Science From Molecules to Population Health|February 20, 2024
A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic DermatitisJulia Tietz, Tea Gunde, Stefan Warmuth, et al.
Oncoimmunology|July 18, 2022
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockadeStefan Warmuth, Tea Gunde, Daniel Snell, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2004
Loss of metal transcription factor-1 suppresses tumor growth through enhanced matrix depositionZishan A Haroon, Khalid Amin, Peter Lichtlen, et al.
Advances in Therapy|April 9, 2021
Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional ConstipationAtoya Adams, Charles Barish, Angel Chen, et al.
Ophthalmology|March 16, 2013
Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eyeMichael A Thiel, Andreas Wild, Martin K Schmid, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 1, 2004
Metal-responsive transcription factor-1 (MTF-1) is essential for embryonic liver development and heavy metal detoxification in the adult liverYing Wang, Ursula Wimmer, Peter Lichtlen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2021
Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term ExtensionMarc A Benninga, Sunny Z Hussain, Manu R Sood, et al.
Oncoimmunology|July 17, 2023
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelinDaniel Snell, Tea Gunde, Stefan Warmuth, et al.
JID Innovations : Skin Science From Molecules to Population Health|February 20, 2024
A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic DermatitisJulia Tietz, Tea Gunde, Stefan Warmuth, et al.
Oncoimmunology|July 18, 2022
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockadeStefan Warmuth, Tea Gunde, Daniel Snell, et al.
Pageof 2